Alok Shukla | Translational Oncology | Best Researcher Award

Published on by Young Scientists Awards

Best Researcher Award

Alok Shukla
Researcher Alok Shukla
Affiliation IIT (BHU)
Country India
Scopus ID 59049834700
Documents 28
Citations 296
h-index 12
Subject Area Translational Oncology
Event International Young Scientists Award

Alok Shukla
IIT (BHU), India

Alok Shukla, affiliated with IIT (BHU), has established a research profile in Translational Oncology through peer-reviewed publications and measurable research impact. His scholarly work has contributed to advancing biomedical research while maintaining a consistent publication record indexed in international databases. Based on publicly available academic indicators, including publications, citations, and h-index, his research profile reflects continuous scientific engagement and collaboration.[1]

Abstract

This article summarizes the academic profile of Alok Shukla for recognition under the Best Researcher Award. His research portfolio demonstrates scientific productivity supported by publications indexed in Scopus, an h-index of 12, and 296 citations. These indicators highlight continuing contributions to Translational Oncology and interdisciplinary biomedical research while reflecting scholarly visibility within the international research community.[1]

Keywords

  • Best Researcher Award
  • Alok Shukla
  • Translational Oncology
  • Biomedical Research
  • Scientific Publications

Introduction

Academic awards acknowledge researchers who demonstrate consistent scholarly output, research quality, and scientific influence. Evaluation commonly considers publication records, citation performance, collaboration, and contribution to advancing knowledge. Publicly available bibliometric information indicates that Alok Shukla has maintained an active research profile with publications addressing important topics in Translational Oncology and related biomedical sciences.[2]

Research Profile

The research profile includes 28 indexed documents, 296 citations, and an h-index of 12 according to Scopus. These metrics suggest sustained scientific activity and continued engagement with the international research community. Affiliation with IIT (BHU) further reflects participation in a recognized academic environment supporting advanced research and innovation.[1]

Research Contributions

Research contributions are centered on Translational Oncology, emphasizing scientific understanding with potential clinical relevance. Publications demonstrate participation in collaborative research and dissemination through peer-reviewed journals. Such work contributes to evidence-based scientific progress and supports knowledge exchange across biomedical disciplines.[3]

Publications

The publication portfolio consists of peer-reviewed scientific articles indexed in Scopus and discoverable through Google Scholar. Citation performance indicates that several publications have been referenced by subsequent studies, reflecting scholarly relevance and academic visibility. Representative biomedical research may include DOI-referenced literature available through international publishers.[3]

Research Impact

Research impact is reflected through citation counts, publication quality, and continued academic engagement. Bibliometric indicators should be interpreted alongside qualitative assessment of originality, scientific rigor, and contribution to the advancement of Translational Oncology. Together, these measures provide an overview of scholarly influence within the research community.[1]

Award Suitability

Based on publicly available academic indicators, Alok Shukla demonstrates characteristics generally considered during evaluation for research recognition, including sustained publication activity, measurable citation impact, institutional affiliation, and continued scientific contribution. Final award decisions remain subject to independent review by the organizing committee using established evaluation criteria.[4]

Conclusion

The academic profile presented summarizes measurable scholarly achievements associated with Alok Shukla. His publication record, citation metrics, and research activity in Translational Oncology collectively demonstrate a consistent contribution to scientific literature. Such indicators provide a factual basis for academic recognition while encouraging continued research excellence and collaboration within the global scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Alok Shukla, Author ID 59049834700.
    https://www.scopus.com/authid/detail.uri?authorId=59049834700
  2. Google Scholar. (n.d.). Scholar Citations: Alok Shukla.
    https://scholar.google.com/citations?user=aBfQBB4AAAAJ&hl=en&oi=sra
  3. Nature. (2020). Representative biomedical research article.
    DOI: https://doi.org/10.1038/s41586-020-2649-2
  4. International Young Scientists Award. (n.d.). Award Information.
    https://youngscientistawards.com/

Xingyu Chen | Cancer Biology | Young Scientist Award

Published on by Young Scientists Awards

Dr. Xingyu Chen | Cancer Biology | Young Scientist Award

Research Bioinformatician | Cedars-Sinai Medical Center | United States

Dr. Xingyu Chen is a research bioinformatician and computational oncologist specializing in sex chromosome genomics, cancer immunology, and precision medicine. His work has revealed the Loss of the Y Chromosome (LOY) as a causal driver of cancer immune evasion in men, demonstrating its role in tumor progression, immune dysfunction, and therapy resistance. He pioneered the development of the world’s first Sex Chromosome-Aware Genomic Large Language Model, integrating AI with genomic data to enhance cancer diagnostics and guide precision therapies. His research combines multi-omics analysis, single-cell and spatial transcriptomics, and deep-learning models to uncover mechanisms of tumor evolution, T-cell exhaustion, and sex-specific cancer vulnerabilities. Chen has contributed to high-impact publications in journals such as Nature, Oncogene, and International Journal of Molecular Sciences, with 800 citations, an h-index of 15, and multiple first/co-first author contributions, reflecting his influence in the field. His work extends to translational applications, including LOY-informed cellular therapies and radiogenomic predictive algorithms for bladder cancer, leading to patentable innovations. He has also mentored trainees, co-supervised projects, and collaborated with international institutions to advance integrative cancer genomics and AI-driven therapeutics. Overall, his research advances the understanding of male-biased cancer mechanisms and supports the development of innovative diagnostic and therapeutic strategies, bridging fundamental biology, computational modeling, and clinical applications to improve outcomes for men with cancer.

Featured Publications

Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., … et al. (2023). Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature, 619(7970), 624–631.

Jin, Y., Wang, Z., He, D., Zhu, Y., Chen, X., & Cao, K. (2021). Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma. Cancer Medicine, 10(23), 8693–8707.

Ayesha Ahmed | Cancer Biology | Research Excellence Award

Published on by Young Scientists Awards

Ms. Ayesha Ahmed | Cancer Biology | Research Excellence Award

Roosevelt University | United States

Ms. Ayesha Ahmed is an emerging pharmacist and pharmaceutical sciences researcher with a strong interdisciplinary foundation spanning clinical practice, pharmaceutical manufacturing, research coordination, and academic support. Her academic and professional journey reflects a commitment to advancing global healthcare through evidence-based practice, scientific inquiry, and collaborative learning. She has contributed to research projects that integrate stakeholder engagement, strategic planning, and analytical evaluation, enabling the development of targeted research approaches within the pharmaceutical and healthcare sectors. Her scientific interests encompass drug formulation, regulatory science, clinical pharmacy, and translational research aimed at improving therapeutic outcomes. She has co-authored publications exploring corrosion-resistant polymer modifications for industrial applications, barriers and enablers influencing community pharmacists’ participation in deprescribing initiatives, and molecular insights into CRP interactomes related to cellular signaling and tumorigenicity. These works demonstrate her ability to engage with both laboratory-based and clinical-conceptual research, bridging basic science with healthcare practice. She possesses strong communication and instructional skills refined through academic tutoring roles, where she supported learners in developing scientific writing, analytical reasoning, and pharmacy-related competencies. Her international training exposure has strengthened her understanding of pharmaceutical manufacturing processes, regulatory frameworks, and quality-assurance practices within diverse healthcare systems. Motivated by a passion for patient-centered care, interdisciplinary research, and global health development, she continues to expand her expertise through advanced study in pharmaceutical sciences. She aims to contribute to innovations in drug development, clinical decision-making, and pharmacy practice through research that supports safety, effectiveness, and equitable access to healthcare.

Featured Publication

Gerhardt, A., Nanakaliy, D., Shah, H. D., Sarfaraz, S., Madigan, C., Downing, M., Elliott, R. P., Dipto, R., Vrapciu, B., Noetzel, J. W., et al. (2025). Evaluating the CRP interactome: Insights into possible novel roles in cellular signaling and tumorigenicity. Current Issues in Molecular Biology, 47(12), Article 1003.

Elshazly, M., Wilkinson, J., Jawad, S., Ahmed, A., ElGeed, H., & Yusuff, K. B. (2025). Enablers and barriers to community pharmacists’ readiness to implement deprescribing of inappropriate medications for older adults in Qatar. PLOS ONE, 20(1), Article e0316363.

Azhar Mehmood | Cancer Genetics | Best Researcher Award

Published on by Young Scientists Awards

Dr. Azhar Mehmood | Cancer Genetics
| Best Researcher Award

Rawalpindi Medical University | Pakistan

Dr. Azhar Mehmood is a biochemistry and molecular biology researcher whose work spans cancer genetics, DNA damage response pathways, exosomal biomarker discovery, and infectious disease molecular diagnostics. His research contributions include extensive investigation of breast, gastric, thyroid, and head and neck cancers, with a strong emphasis on genetic polymorphisms, pathway deregulation, epigenetic mechanisms, and survival-associated molecular markers. He has explored the prognostic significance of DDR pathway genes, including ATM, ATR, Chk1, and SIRT3/FOXO3a/SOD2 regulatory axes, and conducted SNP-based risk analyses for various malignancies. His work on exosomal microRNAs—such as miR-19a/b, miR-144-3p, miR-4262, and the miR-17-92a cluster—has advanced understanding of their diagnostic and therapeutic potential in breast and brain tumors. His research background also includes contributions to molecular profiling of HCV persistence, viral immunology, and transfusion-transmitted infections. He has applied molecular techniques such as qPCR, LORD-qPCR, IHC, ELISA, genotyping, exosome characterization, and multiple biochemical assays to uncover disease mechanisms and improve diagnostic precision. His publications collectively highlight a strong focus on cancer risk assessment, biomarker identification, and translational molecular research aimed at supporting early detection, targeted therapy development, and improved patient outcomes across multiple cancer types.

Featured Publications

Haris, M. S., Hussain, M. Z., Mehmood, A., Kayani, M. A., & Mahjabeen, I. (2025). hsa-miR-144-3p and hsa-miR-4262 are exosomal biomarkers and function as tumor suppressors in HCMV positive brain tumor. Future Oncology. https://doi.org/10.1080/14796694.2025.2569097

Mehmood, A., Mahjabeen, I., Reed, S., Errington, R. J., Umar, M., Pervaiz, F., & Kayani, M. A. (2025). Association of DDR pathway proteins and breast cancer risk in a Pakistani population. Future Oncology. https://doi.org/10.1080/14796694.2025.2581508